title: Partially mismatched blood cell transplants for high-risk hematologic malignancy.
abstract: Eleven patients with high-risk hematologic malignancy received cryopreserved but otherwise unmanipulated blood cell transplants (BCT) from partially mismatched family members in whom progenitor cells had been mobilized by G-CSF. Donors were mismatched by up to one antigen in the GVH direction and up to three antigens in the rejection direction. Outcomes were compared with those of 22 patients receiving BCT from fully matched donors. Two mismatched patients died without engraftment on day 21 and 32. One had rejected bone marrow from the same donor, the other was mismatched by two antigens in the rejection direction and received the lowest dose of CD34+ cells. Median time to granulocyte engraftment was 21.5 (range 16-33) days for the mismatched group compared with 16 (11-28) days for the matched group (P = 0.01). No correlation was found between CD34+ cell dose and time to granulocyte or platelet recovery. In the mismatched and matched BCT groups respectively, the risk of grade II-IV acute graft-versus-host disease (GVHD) was 73% vs 28% (P = 0.001) and of chronic GVHD 100% vs 78% at 18 months (P = 0.01). The relationship of T cell dose to acute GVHD could only be evaluated in the matched group and no correlation was found. One of 11 mismatched patients and eight of 22 matched patients had relapse or persistent disease. Disease-free survival at 1 year was similar at 55% for mismatched and 50% for matched BCT. These results indicate that allogeneic BCT from partially mismatched family members is accompanied by a high incidence of GVHD but may result in comparable survival to BCT from fully matched donors.
authors.affiliation: Alberta Bone Marrow Transplant Program, Foothills Hospital, Calgary, Edmonton, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
authors.forename: S
authors.initials: S
authors.lastname: Desai
authors.forename: B
authors.initials: B
authors.lastname: Herbut
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Luider
authors.forename: J D
authors.initials: JD
authors.lastname: Ruether
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: A
authors.initials: A
authors.lastname: Chaudhry
authors.forename: K
authors.initials: K
authors.lastname: Booth
authors.forename: K
authors.initials: K
authors.lastname: Jorgenson
authors.forename: M J
authors.initials: MJ
authors.lastname: Coppes
authors.forename: A R
authors.initials: AR
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Larratt
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
authors.forename: J
authors.initials: J
authors.lastname: Klassen
mesh_terms: D000293:Adolescent; D000328:Adult; D001788:Blood Grouping and Crossmatching; D002648:Child; D002675:Child, Preschool; D005260:Female; D006085:Graft Survival; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous; D016896:Treatment Outcome